Unibest
← Back to patent-cliff list

Olaparib

Tier A — Act now

Olaparib · all drugs expiring in 2028 →

AstraZeneca
Originator
2014
First approval
2028
Expiry (public)
$4.73B ▲
Peak sales
Small molecule
Type

Targets：PARP-2, PARP-3, PARP1

Brand：Lynparza

Indications (approved)：Endometrial cancer, Castration-resistant prostate cancer, Prostate cancer, Peritoneal cancer, Epithelial ovarian cancer, Fallopian tube cancer, Pancreatic cancer, Ovarian cancer

Regional status

US
Approved
2014-12-19
EU
Approved
2014-12-16
China
Approved
2018-08-22
Japan
Approved
2018-01-19

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 6 · Total yield 1.27 kg
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
OLAP-00116859-59-9Available3-hydroxyisobenzofuran-1(3H)-one
OLAP-002868-85-9Availabledimethyl phosphonate
OLAP-00361260-15-9Availabledimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate
OLAP-004218301-22-5Available2-fluoro-5-formylbenzonitrile
OLAP-005763114-25-6Available(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile
OLAP-006763114-26-7Available2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
OLAP-00757260-71-6Availabletert-butyl piperazine-1-carboxylate
OLAP-008763114-04-1Availabletert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate
OLAP-009763111-47-3Available4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one
OLAP-0104023-34-1Availablecyclopropanecarbonyl chloride
OptimisedRoute 2Steps 6 · Total yield 8.67 g
Synthetic routes & intermediates Route 2
CodeCAS No.Intermediate
OLAP-00116859-59-9Available3-hydroxyisobenzofuran-1(3H)-one
OLAP-004218301-22-5Available2-fluoro-5-formylbenzonitrile
OLAP-005763114-25-6Available(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile
OLAP-006763114-26-7Available2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
OLAP-0104023-34-1Availablecyclopropanecarbonyl chloride
OLAP-0111021298-68-9Available2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile
OLAP-0121021298-67-8Availablecyclopropyl(piperazin-1-yl)methanone hydrochloride
OLAP-013110-85-0Availablepiperazine

Frequently asked questions

What are the approved indications of Olaparib?

Approved indications include: Endometrial cancer, Castration-resistant prostate cancer, Prostate cancer, Peritoneal cancer, Epithelial ovarian cancer, Fallopian tube cancer, Pancreatic cancer, Ovarian cancer.

When does the Olaparib patent expire?

Based on public sources, the Olaparib patent expires in 2028.

How many synthesis routes are recorded for Olaparib?

2 synthesis routes are recorded; the shortest is 6 steps with 1.27 kg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Olaparib intermediates?

13 intermediate CAS of Olaparib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Olaparib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29